Coave Therapeutics, a genetic medicine company focused on developing innovative therapies, is pleased to announce its receipt of a grant from the ALS Association, part of a $2.9 million allocation to six organizations. These grants support the advancement of treatments for amyotrophic lateral sclerosis (ALS), with Coave's grant specifically aiding its CTx-TFEB program through preclinical proof-of-concept.

ALS is a progressive neurodegenerative disease affecting nerve cells in the brain and spinal cord, leading to loss of movement, speech, and eventually breathing. Despite various genetic links, most cases are sporadic, posing challenges in diagnosis and with no current cure.

A common feature of ALS and other neurodegenerative diseases is the accumulation of toxic protein aggregates within neurons, contributing to their degeneration. Coave's CTx-TFEB program seeks to enhance autophagy, the cellular process responsible for clearing these aggregates, offering a potential pan-ALS therapy.

CTx-TFEB utilizes Coave's ALIGATER™ platform, employing a specialized viral vector (coAAV) to deliver the TFEB gene directly to neurons. TFEB, a crucial regulator of autophagy, aids in clearing protein aggregates. By activating TFEB, Coave aims to restore autophagy function, potentially halting ALS progression.

Coave Therapeutics, expressed optimism for the potential of TFEB gene therapy to preserve muscular function in ALS patients by clearing toxic material from neurons. With the support of the ALS Association grant, Coave aims to progress its CTx-TFEB program toward clinical trials, emphasizing their shared commitment to ALS patients.

Kuldip Dave, Ph.D., Senior Vice President of Research at the ALS Association, stressed the urgency of developing effective ALS treatments and commended Coave and other grant recipients for their efforts in advancing potential therapies from preclinical to clinical stages. Dave highlighted the importance of accelerating promising treatments into clinical trials to improve the lives of ALS patients until a cure is discovered.

 

Source: globenewswire.com

Report Abuse